Abstract：Obesity is a kind of metabolic disease, which is a major risk factor of heart disease, diabetes mellitus and cancer. In recent years, the US Food and Drug Administration (FDA) has approved a stand of drugs treatment for obesity, including sibutramine, orlistat, belviq and so on,however, side effects may occur after long-term using. Celastrol is a class of pentacyclic triterpenoids extracted from the roots of Tripterygium wilfordii Hook F. It has been found that celastrol has the pharmacological activities of increasing leptin sensitivity, increasing fat metabolism, inhibiting the formation of lipocyte and inhibiting chronic inflammation in obesity animals. This overview summarizes the related mechanisms of celastrol on treatment of obesity to provide enlightenments for its further study.
ZENG Z, LIN X, ZHENG R, et al. Celastrol alleviates airway hyperresponsiveness and inhibits Th17 responses in obese asthmatic mice[J]. Front Pharmacol, 2018, 9: 49.
[2]
ARAGONES G, ARDID-RUIZ A, IBARS M, et al. Modulation of leptin resistance by food compounds[J]. Mol Nutr Food Res, 2016, 60(8): 1789-1803.
[3]
LEE J, LIU J, FENG X, et al. Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice[J]. Nat Med, 2016, 22(9): 1023-1032.
[4]
LIANG R, LI X, ZHANG R, et al. Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice[J]. Pharm Res, 2014, 31(8):1958-1966.
[5]
FERRANTE A W JR. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation[J]. J Intern Med, 2007, 262(4): 408-414.
[6]
SPIEZIO S H, AMON L M, MCMILLEN T S, et al. Genetic determinants of atherosclerosis, obesity, and energy balance in consomic mice[J]. Mamm Genome, 2014, 25(11-12): 549-563.
[7]
CHEN S R, DAI Y, ZHAO J, et al. A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F[J]. Front Pharmacol, 2018, 9: 104.
[8]
ZHOU Z L, YANG Y X, DING J, et al. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms[J]. Nat Prod Rep, 2012,29(4): 457-475.
[9]
SU P, GUAN H, ZHAO Y, et al. Identification and functional characterization of diterpene synthases for triptolide biosynthesis from Tripterygium wilfordii[J]. Plant J, 2018, 93(1): 50-65.
[10]
HANG H, ZENG Z Y, WANG L, et al. Effect of celastrol on airway inflammation and Th17 cells in obese asthmatic mice[J]. Chin Pharm J(中国药学杂志), 2019, 54(7): 542-548.
[11]
SHEN Y F, ZHANG X, WANG Y, et al. Celastrol targets IRAKs to block Toll-like receptor 4-mediated nuclear factor-κB activation[J]. J Integr Med, 2016,14(3): 203-208.
[12]
LI H Y, ZHANG J, SUN L, et al. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study[J]. Cell Death Dis, 2015,22(6):e1604.
[13]
XIN W, WANG Q, ZHANG D, et al. A new mechanism of inhibition of IL-1β secretion by celastrol through the NLRP3 inflammasome pathway[J]. Eur J Pharmacol, 2017, 814(5):240-247.
[14]
LIU B Y, TONG N S, LI Y Y, et al. Hypoglycemmic mechanism of polygonum capitatum extract on spontaneous model of type 2 diabetic db/db mice[J]. Chin Pharm J(中国药学杂志), 2017, 52(5): 384-390.
[15]
VAN DOORN C, MACHT V A, GRILLO C A, et al. Leptin resistance and hippocampal behavioral deficits[J]. Physiol Behav, 2017, 1(176):207-213.
[16]
LIU J, LEE J, SALAZAR HERNANDEZ M A, et al. Treatment of obesity with celastrol[J]. Cell, 2015,161(5): 999-1011.
[17]
GREENHILL C. Celastrol identified as a leptin sensitizer and potential novel treatment for obesity[J]. Nat Rev Endocrinol, 2015, 11(8): 444.
[18]
AL-MASHHADI A L, POULSEN C B, VON WACHENFELDT K, et al. Diet-induced abdominal obesity, metabolic changes, and atherosclerosis in hypercholesterolemic minipigs[J]. J Diabet Res, 2018, 2018: 6823193.
[19]
CRUNKHORN S. Metabolic disease: leptin sensitizer reverses obesity[J]. Nat Rev Drug Discov, 2016,15(9): 601.
[20]
FENG X, GUAN D, AUEN T, et al. IL1R1 is required for celastrol's leptin-sensitization and antiobesity effects[J]. Nat Med, 2019.
[21]
KYRIAKOU E, SCHMIDT S, DODD G T, et al. Celastrol promotes weight loss in diet-induced obesity by inhibiting the protein tyrosine phosphatases PTP1B and TCPTP in the hypothalamus[J]. J Med Chem, 2018, 61(24):11144-11157.
[22]
POLEDNE R, LESNA I K. Inflammation and atherosclerosis[J]. Vnitrni Lekarstvi, 2019,64(12): 1142-1146.
[23]
CHOI S K, PARK S, JANG S, et al. Cascade regulation of PPARgamma(2) and C/EBPalpha signaling pathways by celastrol impairs adipocyte differentiation and stimulates lipolysis in 3T3-L1 adipocytes[J]. Metabolism, 2016,65(5): 646-654.
[24]
FARMER S R. Transcriptional control of adipocyte formation[J]. Cell Metab, 2006,4(4): 263-273.
[25]
MAJDALAWIEH A, RO H S. PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1[J]. Nucl Recept Signal, 2010,8: e004.
[26]
WU J S, KAO M H, TSAI H D, et al. Clinacanthus nutans mitigates neuronal apoptosis and ischemic brain damage through augmenting the C/EBPbeta-Driven PPAR-gamma transcription[J]. Mol Neurobiol, 2018, 55(7): 5425-5438.
[27]
HONG W, PARK J, YUN W, et al. Inhibitory effect of celastrol on adipogenic differentiation of human adipose-derived stem cells[J]. Biochem Biophys Res Commun, 2018, 507(1-4):236-241.
[28]
WANG T, WEI X J, WANG X G, et al. Effects of astragalus polysaccharides on the insulin sensitivity in the fat rats[J]. Chin Pharm J(中国药学杂志), 2011,46(3): 185-188.
[29]
LI M, WU C, GUO H, et al. Mangiferin improves hepatic damage-associated molecular paternss lipid metabolic disorder and mitochondrial dysfunction in alcohol hepatitis tats[S]. Food Funct, 2019,10(6):3514-3534.
[30]
SHI Y, ZHANG W, CHENG Y, et al. Bromide alleviates fatty acid-induced lipid accumulation in mouse primary hepatocytes through the activation of PPARalpha signals[J]. J Cell Mol Med, 2019, 23(6): 4464-4474.
[31]
ZHANG X, WANG Y, GE H Y, et al. Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA [J]. J Cell Physiol, 2018, 233(10): 6814-6824.
[32]
GUAN Y, CUI Z J, SUN B, et al. Celastrol attenuates oxidative stress in the skeletal muscle of diabetic rats by regulating the AMPK-PGC1alpha-SIRT3 signaling pathway [J]. Int J Mol Med, 2016, 37(5): 1229-1238.
[33]
ABU BAKAR M H, TAN J S. Improvement of mitochondrial function by celastrol in palmitate-treated C2C12 myotubes via activation of PI3K-Akt signaling pathway[J]. Biomed Pharmacother, 2017, 93: 903-912.
[34]
KIM J E, LEE M H, NAM D H, et al. Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice [J]. PLoS One, 2013, 8(4): e62068.
[35]
KIM J, KWON J, KIM M, et al. Low-dielectric-constant polyimide aerogel composite films with low water uptake [J]. Polymer Journal, 2016, 48: 829-834.
[36]
XU L, ZHAO W, WANG D, et al. Chinese medicine in the battle against obesity and metabolic diseases [J]. Front Physiol, 2018, 9(6): 850.
[37]
SELL H, POITOU C, HABICH C, et al. Heat shock protein 60 in obesity: effect of bariatric surgery and its relation to inflammation and cardiovascular risk [J]. Obesity (Silver Spring, Md), 2017, 25(12): 2108-2114.
[38]
ANCKAR J, SISTONEN L. Regulation of HSF1 function in the heat stress response: implications in aging and disease[J]. Annu Rev Biochem, 2011, 80: 1089-1115.
[39]
MA X, XU L, AIBEROBELLO A T, et al. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1alpha transcriptional axis[J]. Cell Metab, 2015, 22(4): 695-708.
[40]
WANG C, SHI C, YANG X, et al. Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism [J]. Eur J Pharmacol, 2014,744: 52-58.
[41]
ZHANG J, SHAN J, CHEN X, et al. Celastrol mediates Th17 and Treg cell generation via metabolic signaling [J]. Biochem Biophys Res Commun, 2018, 497(3): 883-889.
[42]
ESSER N, LEGRAND-POELS S, PIETTE J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes[J]. Diabetes Res Clin Pract, 2014, 105(2): 141-150.
[43]
MACEDO F, DOS SANTOS L S, GLEZER I, et al. Brain innate immune response in diet-induced obesity as a paradigm for metabolic influence on inflammatory signaling [J]. Front Neur, 2019, 13: 342.
[44]
LUO D, GUO Y, CHENG Y, et al. Natural product celastrol suppressed macrophage M1 polarization against inflammation in diet-induced obese mice via regulating Nrf2/HO-1, MAP kinase and NF-kappaB pathways[J]. Aging, 2017, 9(10): 2069-2082.
[45]
FARZANEGI P, DANA A, EBRAHIMPOOR Z, et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation[J]. Eur J Sport Sci, 2019,19(7):994-1003.
[46]
GUO R, LIONG E C, SO K F, et al. Beneficial mechanisms of aerobic exercise on hepatic lipid metabolism in non-alcoholic fatty liver disease[J]. Hepatobiliary Pancreat Dis Int, 2015,14(2):139-144.
[47]
ZHANG Y, GENG C, LIU X, et al. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1 [J]. Mol Metab, 2017, 6(1): 138-147.
[48]
PFLUGER P T, HERRANZ D, VELASCO-MIGUEL S, et al. Sirt1 protects against high-fat diet-induced metabolic damage[J]. Proc Natl Acad Sci USA, 2008, 105(28): 9793-9798.
2020, Vol. 55 
